Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Neurokinin 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma japonicum | ko:K04224 tachykinin receptor 3, putative | Get druggable targets OG5_137770 | All targets in OG5_137770 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma japonicum | ko:K04209 neuropeptide Y receptor, invertebrate, putative | Neurokinin 1 receptor | 407 aa | 352 aa | 25.3 % |
Schistosoma japonicum | ko:K04145 dopamine receptor D2, putative | Neurokinin 1 receptor | 407 aa | 387 aa | 18.1 % |
Echinococcus multilocularis | thyrotropin releasing hormone receptor | Neurokinin 1 receptor | 407 aa | 342 aa | 22.2 % |
Echinococcus granulosus | thyrotropin releasing hormone receptor | Neurokinin 1 receptor | 407 aa | 341 aa | 22.0 % |
Echinococcus multilocularis | allatostatin A receptor | Neurokinin 1 receptor | 407 aa | 347 aa | 24.8 % |
Echinococcus granulosus | allatostatin A receptor | Neurokinin 1 receptor | 407 aa | 347 aa | 24.8 % |
Schistosoma mansoni | neuropeptide F-like receptor | Neurokinin 1 receptor | 407 aa | 333 aa | 21.0 % |
Schistosoma japonicum | ko:K04135 adrenergic receptor, alpha 1a, putative | Neurokinin 1 receptor | 407 aa | 373 aa | 22.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | ubiquitin-conjugating enzyme E2, putative | 0.0124 | 0.7803 | 0.5 |
Echinococcus granulosus | ubiquitin conjugating enzyme E2 N | 0.0124 | 0.7803 | 0.6596 |
Trypanosoma cruzi | ubiquitin-conjugating enzyme E2, putative | 0.0124 | 0.7803 | 0.5 |
Echinococcus granulosus | furin | 0.0143 | 1 | 1 |
Echinococcus multilocularis | neuroendocrine convertase 2 | 0.009 | 0.3886 | 0.0798 |
Plasmodium falciparum | ubiquitin-conjugating enzyme E2 N, putative | 0.0124 | 0.7803 | 0.5 |
Echinococcus multilocularis | 0.0116 | 0.6817 | 0.7684 | |
Loa Loa (eye worm) | hypothetical protein | 0.0143 | 1 | 1 |
Brugia malayi | celfurPC protein | 0.0116 | 0.6817 | 0.4795 |
Entamoeba histolytica | ubiquitin-conjugating enzyme family protein | 0.0124 | 0.7803 | 0.5 |
Toxoplasma gondii | ubiquitin-conjugating enzyme subfamily protein | 0.0124 | 0.7803 | 0.5 |
Brugia malayi | ubiquitin conjugating enzyme protein 13 | 0.0124 | 0.7803 | 0.6407 |
Loa Loa (eye worm) | ubiquitin conjugating enzyme protein 13 | 0.0124 | 0.7803 | 0.7803 |
Schistosoma mansoni | ubiquitin conjugating enzyme 13 | 0.0124 | 0.7803 | 0.7637 |
Brugia malayi | Ubiquitin conjugating enzyme protein 13 | 0.0124 | 0.7803 | 0.6407 |
Loa Loa (eye worm) | ubiquitin conjugating enzyme protein 13 | 0.0124 | 0.7803 | 0.7803 |
Schistosoma mansoni | subfamily S8B unassigned peptidase (S08 family) | 0.0143 | 1 | 1 |
Echinococcus multilocularis | ubiquitin conjugating enzyme E2 N | 0.0124 | 0.7803 | 1 |
Loa Loa (eye worm) | endoprotease bli-4 | 0.0143 | 1 | 1 |
Plasmodium vivax | ubiquitin-conjugating enzyme E2 N, putative | 0.0124 | 0.7803 | 0.5 |
Trypanosoma brucei | ubiquitin-protein ligase, putative | 0.0124 | 0.7803 | 0.5 |
Leishmania major | ubiquitin-conjugating enzyme e2, putative | 0.0124 | 0.7803 | 0.5 |
Trichomonas vaginalis | ubiquitin-conjugating enzyme E2, putative | 0.0124 | 0.7803 | 1 |
Echinococcus granulosus | neuroendocrine convertase 2 | 0.009 | 0.3886 | 0.0526 |
Trichomonas vaginalis | ubiquitin-conjugating enzyme E2, putative | 0.0124 | 0.7803 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0.15 nM | Antagonism of NK1 receptor in rat liver microsomes. | ChEMBL. | No reference |
IC50 (functional) | = 0.15 nM | Antagonism of NK1 receptor in rat liver microsomes. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.